A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION STUDY OF PRT1419 INJECTION AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MYELOID OR B-CELL MALIGNANCIES
- Registry ID
- PRT1419-03
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- PRELUDE THERAPEUTICS
- Completion date
- 2023-10-19
- Last update
- 2023-05-31
Conditions
- MANTLE CELL LYMPHOMA
- FOLLICULAR LYMPHOMA
- B-CELL NON-HODGKIN'S LYMPHOMA
- MYELOPROLIFERATIVE NEOPLASMS
- CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML-2)
- MYELODYSPLASTIC SYNDROME
- SMALL LYMPHOCYTIC LYMPHOMA
- ACUTE MYELOID LEUKEMIA
- CHRONIC LYMPHOCYTIC LEUKEMIA
Related clinical trials
- A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF INCA036978 IN PARTICIPANTS WITH MYELOPROLIFERATIVE NEOPLASMS
- A PHASE 1/2 OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND CLINICAL ACTIVITY OF GSK5926371 IN ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
- A PHASE II STUDY OF SONROTOCLAX PLUS ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PLANNED FOR STANDARD OF CARE CAR-T CELL THERAPY
- A PHASE III, RANDOMISED, OPEN-LABEL, MULTICENTRE, STUDY OF SUROVATAMIG AS CONSOLIDATION THERAPY VERSUS OBSERVATION AFTER FIRST-LINE INDUCTION THERAPY IN PARTICIPANTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WITH UNMUTATED IGHV (SOUNDTRACK-C1)
- A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF INCB160058 IN PARTICIPANTS WITH MYELOPROLIFERATIVE NEOPLASMS
- PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES ASSESSING
ZIFTOMENIB IN COMBINATION WITH EITHER STANDARD OF CARE NONINTENSIVE
(VENETOCLAX+AZACITIDINE) OR INTENSIVE (7+3) THERAPY IN PATIENTS WITH
UNTREATED NPM1 MUTATED OR KMT2A REARRANGED ACUTE MYELOID LEUKEMIA
View on source registry